Absci Corp ABSI

$9.14 -0.98 (-9.68%)

Valuation

Market cap
1,710,991,000
Revenue TTM
$2,800,000
Net income TTM
$-115,180,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-4,113.57%
Debt to equity
0.00

Trading

Volume
4,918,000
Avg volume
4,024,536
Day's range
$8.96 – $9.94
Shares out
171,614,000
Stochastic %K
40%
Beta
2.22
Analysts
Strong Buy
Price target
$14.82

Price

Company profile

Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-...

Show more

Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.

Industry
Biotechnology
Sector
Healthcare
Phone
360 949 1041
Website
https://www.absci.com
Address
18105 SE Mill Plain Boulevard, Vancouver, United States

Latest news

Stocktwits

7m3835d3 Nov 12, 7:55 PM
$ABSI i’m pretty excited about the two new open label female arms for hair growth at 300mg and 1200mg. They don’t need to run an additional placebo controlled blinded study for this, but this gives them the opportunity to continuously monitor safety, PK and efficacy. This is very important, as this data will be used to determine the ideal dosing regimen for phase 2 endometriosis. So we are getting two questions answered: 1) does ABS-201 also lead to hair growth in female patients (which would be huge), and 2) what dose might work best for PRLR occupation in females patients withiut causing any side effects? I really like the way they are executing this. Excited for what’s ahead!
0 replies
oldwisetrader Nov 12, 3:33 PM
$QURE with the $NVDA news I’m seeing fund flows into healthcare and biotech ,, love $QURE and own it in long term account , looks like it’s on its way back to $30 .. buyouts into year in is always a good year end strategy , $ABSI $RXRX $SMMT
0 replies
jfat2hee2 Nov 12, 2:34 PM
$ABSI may God have mercy on our souls
0 replies
EarningsInsider Nov 12, 2:16 PM
https://www.marketbeat.com/earnings/reports/2026-11-12-absci-corp-stock/ $ABSI Absci Earnings Transcript
0 replies
CRMDiamondhands Nov 12, 2:04 PM
$ABSI did anyone hear anything that would justify this drop? Or is this just the cycle running its course again?
1 replies
teaman60 Nov 12, 1:22 PM
$ABSI glad I issued my SCAM ALERT. I was correct in doing so.
1 replies
d_risk Nov 12, 12:49 PM
$ABSI Absci Corporation | 10Q Updated Risk Factors Absci says it will seek a partner for ABS-101 after Phase 1 and does not plan to pursue further internal clinical development. #RiskFactors #SECFilings 🟢 Added 🟠 Removed https://d-risk.ai/ABSI?filing=gPwgUzggic0twwmq87sAY
0 replies
AntJustTrades Nov 12, 12:37 PM
$ABSI Absci confirmed that its 13-week interim proof-of-concept results for ABS-201 in pattern hair loss are expected next month. Full 26-week results are anticipated in early 2027. This is arguably the most important development in the entire earnings report. Absci appointed Gerry Muhle, a former Galderma executive with more than 25 years of experience in pharmaceuticals, aesthetics and consumer brands, as Chief Commercial Officer. This signals that management is preparing for eventual commercialization, although approval is still uncertain. Super high upside potential for data numbers in December. Stay tuned 📌
0 replies